ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03451045
Recruitment Status : Recruiting
First Posted : March 1, 2018
Last Update Posted : November 16, 2018
Sponsor:
Collaborator:
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
Corbus Pharmaceuticals Inc.

Brief Summary:

This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12 years of age or older. Approximately 415 subjects will be enrolled in this study at about 100 sites in North America, Europe, and Australia. The planned duration of treatment with study drug is 28 weeks.

Study drug will be lenabasum 20 mg BID, lenabasum 5 mg BID, and placebo in a 2:1:2 ratio.


Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: Lenabasum 20 mg Drug: Lenabasum 5 mg Other: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 415 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multicenter, double-blind, randomized, placebo-controlled, parallel group study.
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Actual Study Start Date : December 22, 2017
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arm Intervention/treatment
Experimental: Lenabasum 20 mg BID Drug: Lenabasum 20 mg
Subjects will receive lenabasum 20 mg twice daily.

Experimental: Lenabasum 5 mg BID Drug: Lenabasum 5 mg
Subjects will receive lenabasum 5 mg twice daily.

Placebo Comparator: Placebo BID Other: Placebo
Subjects will receive placebo twice daily.




Primary Outcome Measures :
  1. Pulmonary Exacerbation (PEx) [ Time Frame: Visit 1 through Week 28. ]
    Rate of PEx using the primary PEx definition with lenabasum 20 mg BID compared to placebo, during the treatment period.


Secondary Outcome Measures :
  1. Pulmonary Exacerbation (PEx) [ Time Frame: Visit 1 through Week 28. ]
    Event rate of PEx using the secondary PEx definition with lenabasum 20 mg BID compared to placebo.

  2. Pulmonary Exacerbation (PEx) [ Time Frame: Visit 1 through Week 28. ]
    Time to first new PEx using the primary PEx definition with lenabasum 20 mg BID compared to placebo.

  3. Pulmonary Exacerbation (PEx) [ Time Frame: Visit 1 through Week 28. ]
    Time to first PEx using the secondary PEx definition with lenabasum 20 mg BID compared to placebo.

  4. Pulmonary Exacerbation (PEx) [ Time Frame: Visit 1 through Week 28. ]
    Event rate of PEx using the primary PEx definition with lenabasum 5 mg BID compared to placebo, during the treatment period.

  5. Pulmonary Exacerbation (PEx) [ Time Frame: Visit 1 through Week 28. ]
    Event rate of PEx using the secondary PEx definition with lenabasum 5 mg BID compared to placebo.

  6. Pulmonary Exacerbation (PEx) [ Time Frame: Visit 1 through Week 28. ]
    Time to first new PEx using the primary PEx definition with lenabasum 5 mg BID compared to placebo.

  7. Pulmonary Exacerbation (PEx) [ Time Frame: Visit 1 through Week 28. ]
    Time to first PEx using the secondary PEx definition with lenabasum 5 mg BID compared to placebo.

  8. CFQ-R respiratory symptom domain [ Time Frame: Visit 1 through Week 28. ]
    Change from baseline in CFQ-R respiratory symptom domain with lenabasum compared to placebo.

  9. FEV1 % predicted [ Time Frame: Visit 1 through Week 28. ]
    Change from baseline in FEV1 % predicted with lenabasum compared to placebo.

  10. Adverse Events [ Time Frame: Visit 1 through Week 28. ]
    Incidence of treatment emergent adverse events with lenabasum treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ≥ 12 years of age at the time Informed Consent/ Assent is signed.
  2. Weight ≥ 40 kg.
  3. FEV1 ≥ 40% predicted and < 100% predicted in the last 12 months.
  4. Physician-initiated treatment with an IV antibiotic 2 or 3 times in the last 12 months for a new PEx or physician-initiated treatment with an IV antibiotic 1 time in the last 12 months plus physician-initiated treatment with oral antibiotic(s) 1 or more times in the past 12 months for a new PEX.

Exclusion Criteria:

  1. Severe or unstable CF at screening or Visit 1.
  2. Any of the following values for laboratory tests at screening:

    1. A positive pregnancy test.
    2. Hemoglobin < 10 g/dL in males and < 9 g/dL in females.
    3. Neutrophils < 1.0 x 10^9 /L.
    4. Platelets < 75 x 10^9/L.
    5. Creatinine clearance < 50 mL/min according to Modification of Diet in Renal Disease (MDRD) Study equation.
    6. Serum transaminases > 2.5 x upper limit of normal.
  3. Any medical condition or concurrent medical therapies at screening or Visit 1 that may put the subject at greater safety risk, influence response to study drug or interfere with study assessments.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03451045


Contacts
Contact: Lindsey Smith 617-977-5030 CFpatients@corbuspharma.com
Contact: Scott Constantine, MS 617-977-5030 CFpatients@corbuspharma.com

  Show 30 Study Locations
Sponsors and Collaborators
Corbus Pharmaceuticals Inc.
Cystic Fibrosis Foundation Therapeutics
Investigators
Principal Investigator: James Chmiel, MD Rainbow Baby and Children's Hospital
Principal Investigator: J. Stuart Elborn, MD National Heart and Lung Institute, Imperial College

Responsible Party: Corbus Pharmaceuticals Inc.
ClinicalTrials.gov Identifier: NCT03451045     History of Changes
Other Study ID Numbers: JBT101-CF-002
First Posted: March 1, 2018    Key Record Dates
Last Update Posted: November 16, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Corbus Pharmaceuticals Inc.:
Pulmonary exacerbation, lenabasum, JBT-101

Additional relevant MeSH terms:
Fibrosis
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases